Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the patients and the physicians, nurses, pharmacists, transplantation coordinators, and other co-medical staff for their care of the patients involved in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Author contributions

TO and KM were involved in the study design and data collection. TO and KM drafted the paper. AH, MY, KN, HM, YM, and MK critically revised the report and commented on drafts of the manuscript. All authors approved the final version of the manuscript.

Disclosure statement

Mineo Kurokawa has received payment for lectures from Takeda Pharmaceutical Company Limited and research grants from Takeda Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Astellas Pharma Inc., and Ono Pharmaceutical Co., Ltd. Kensuke Matsuda and Akira Honda have received payment for lectures from Kyowa Kirin Co., Ltd. and Nippon Shinyaku Co., Ltd., respectively. This is not related to the current study. The other authors declare no competing financial interests.